Ilaris 150 mg/mL
canakinumab · INJECTION, SOLUTION · Novartis Pharmaceuticals Corporation
No Recall History
Plain English
Ilaris is a injection, solution containing canakinumab at 150 mg/mL, taken subcutaneous. Manufactured by Novartis Pharmaceuticals Corporation.
Key Facts
- Brand Name
- Ilaris
- Generic Name
- canakinumab
- NDC Code (Product)
0078-0734- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 150 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA125319
- Marketing Start
- 12/22/2016
Recall History
No Recall HistoryFrequently Asked Questions
What is Ilaris used for?
Ilaris contains canakinumab. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Ilaris a controlled substance?
Ilaris is not classified as a controlled substance by the DEA.
What is the generic name for Ilaris?
The generic name for Ilaris is canakinumab. There are no other listed brand versions of canakinumab.
What is the NDC code for Ilaris 150 mg/mL?
The NDC (National Drug Code) for Ilaris 150 mg/mL is 0078-0734, listed by Novartis Pharmaceuticals Corporation.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)